Skip to content

Lung Cancer Research Studies

Most cited papers

  1. Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine · 2004 · 11,565 citations
  2. EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience · 2004 · 9,452 citations
  3. Gefitinib or Carboplatin–Paclitaxel in Pulmonary AdenocarcinomaNew England Journal of Medicine · 2009 · 8,355 citations
  4. Pembrolizumab for the Treatment of Non–Small-Cell Lung CancerNew England Journal of Medicine · 2015 · 6,294 citations
  5. Comprehensive molecular profiling of lung adenocarcinomaNature · 2014 · 5,803 citations
  6. Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung CancerNew England Journal of Medicine · 2006 · 5,796 citations
  7. Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFRNew England Journal of Medicine · 2010 · 5,571 citations
  8. Erlotinib in Previously Treated Non–Small-Cell Lung CancerNew England Journal of Medicine · 2005 · 5,451 citations
  9. Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung CancerNew England Journal of Medicine · 2002 · 5,254 citations
  10. Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung CancerNew England Journal of Medicine · 2010 · 4,480 citations
  11. EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinibProceedings of the National Academy of Sciences · 2004 · 4,371 citations

Metadata from OpenAlex (CC0).